Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

Västra Hamnen Market Focus: Xintela: Interim phase I/IIa data coming up

Xintela
  • Interim data from the OA study expected by the end of Q1
  • Additional patients recruited in the VLU study
  • Our model suggests a fair value of SEK 1.43 per share

The interim analysis from the knee osteoarthritis study with XSTEM is expected by the end of Q1 2025. The readout is of great significance for Xintela’s lead project. In the difficult-to-heal leg ulcer (VLU) study, five patients have been recruited, four have completed the study. The company is investigating the possibility of moving to the next step, as no safety issues have been observed. There is no update regarding the process with EQGen Biomedical regarding EQSTEM. We expect the process with Region Östergötland to advance as planned. Minor adjustments to our model suggest a fair value of SEK 1.43 per share.

Read the full report here.

About Market Focus


The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.